Stryker’s longtime CEO moves to executive chair in January 2027 after tripling sales. His successor gets a well-oiled company, a calm handover and very little room for error.
Nobody at Stryker will be scrambling this week. The company announced that Kevin Lobo will step down as chief executive on January 1, 2027, and become executive chair of the board. Spencer Stiles, the current president and COO, gets the top job and a board seat on the same day.
If you’ve watched Stryker over the past few years, you saw this coming. Stiles has been the heir apparent for a while now. He came up through the business, ran some of its biggest divisions and, as COO, was already handling a lot of what a CEO handles. The announcement mostly makes official what the industry had assumed.
We think that’s a good thing. Medtech has had its share of messy CEO changes lately, the kind that come with a new strategy deck, a round of layoffs and a “portfolio review” that ends with something being sold. Stryker is doing the opposite. And for a company that’s been growing as steadily as this one, dull is exactly what shareholders should want.
A hard act to follow
Lobo took over in October 2012, when Stryker was doing $8.7 billion a year in sales. It will close out his tenure above $26 billion. That’s a tripling in 14 years, in an industry where reimbursement squeezes and regulators make every dollar of growth harder to earn than it looks.
Much of it was bought. Stryker did more than 60 deals under Lobo, and he was rarely shy about writing big checks. The one people will remember is Mako. When Stryker picked up the robotic-arm company back in 2013, plenty of analysts were skeptical. A decade later, Mako is arguably the reason Stryker owns the conversation around robotic knee and hip surgery. Wright Medical gave it a real foothold in extremities. Inari Medical, more recently, pushed it into peripheral vascular.
What’s easier to overlook is how Lobo ran the place. Stryker is organized into fairly independent, specialized units that sell into very specific customer groups, and that setup has a lot to do with why its growth has been so consistent compared with peers that tried to run everything from the center.
The fine print
Keeping Lobo around as executive chair makes sense on paper. He knows the big hospital customers, he knows the deal pipeline, and the board clearly wants a soft landing. But these arrangements can get awkward. A long-serving boss who stays in the building doesn’t always find it easy to let go, and a new CEO needs to be seen calling the shots. How that plays out in 2027 is worth watching.
What Stiles walks into
The bar is high, and Wall Street won’t grade on a curve. The working assumption is that Stryker keeps putting up high-single-digit organic growth and keeps acquiring its way into faster-growing markets. Anything less will be read as a step back, fair or not.
He also gets a tougher hand than Lobo had in 2012. Hospitals are pushing hard on price. Tariffs have made supply chains a boardroom topic again. The competitive map in orthopedics is shifting, with Johnson & Johnson moving to spin off its orthopaedics business. And the robotics race is opening up beyond knees and hips, where Stryker has a head start but certainly not the field to itself.
None of this is a reason to worry about the pick. Stiles knows the company, the timing is calm, and the outgoing CEO isn’t going anywhere. The real test is whether the next few years show that Stryker’s run was built into the company itself and not just into the man at the top. If Stiles can keep the machine running and land a couple of smart deals along the way, this will go down as a textbook handover. If growth stalls, the comparisons with Lobo will start fast.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.